#######################
# Document Properties #
#######################
SET DOCUMENT Copyright   = "Copyright Â© 2019 Fraunhofer Institute SCAI, All rights reserved."
SET DOCUMENT Licenses    = "CC BY 4.0"
SET DOCUMENT ContactInfo = "charles.hoyt@scai.fraunhofer.de"

SET DOCUMENT Name        = "First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer's disease model"
SET DOCUMENT Version     = "1.0.0"
SET DOCUMENT Authors     = "Yojana Gadiya"
SET DOCUMENT Description = ""

##############
# Namespaces #
##############

# Namespaces hosted on https://github.com/pharmacome/conso
# --------------------------------------------------------
# DEFINE NAMESPACE CHEBI          AS URL "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/chebi-names.belns"
 DEFINE NAMESPACE CONSO          AS URL "https://raw.githubusercontent.com/pharmacome/conso/f1d67b769276bdf8226e747789346b7a8ff6f296/export/conso-names.belns"
# DEFINE NAMESPACE DRUGBANK       AS URL "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/drugbank-names.belns"
 DEFINE NAMESPACE DOID           AS URL "https://raw.githubusercontent.com/pharmacome/conso/c0c576e3d3ab9b25a3982251a4ee2fd7c49e1679/external/doid-names.belns"
# DEFINE NAMESPACE ECCODE         AS URL "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/ec-code.belns"
# DEFINE NAMESPACE EFO            AS URL "https://raw.githubusercontent.com/pharmacome/conso/5d2c2ea6f7112421cc8089a3f021a75ab60bb373/external/efo-names.belns"
# DEFINE NAMESPACE FB             AS URL "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/fb-names.belns"
DEFINE NAMESPACE HGNC           AS URL "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/hgnc-names.belns"
# DEFINE NAMESPACE HGNCGENEFAMILY AS URL "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/hgnc.genefamily-names.belns"
# DEFINE NAMESPACE HP             AS URL "https://raw.githubusercontent.com/pharmacome/conso/d9d270e11aac480542c412d4222983a5f042b8ae/external/hp-names.belns"
 DEFINE NAMESPACE GO             AS URL "https://raw.githubusercontent.com/pharmacome/conso/d9d270e11aac480542c412d4222983a5f042b8ae/external/go-names.belns"
# DEFINE NAMESPACE INTERPRO       AS URL "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/interpro-names.belns"
 DEFINE NAMESPACE MESH           AS URL "https://raw.githubusercontent.com/pharmacome/conso/f02c6ad4a4791a8ed45448513b9de8c8f1b00c87/external/mesh-names.belns"
# DEFINE NAMESPACE MGI            AS URL "https://raw.githubusercontent.com/pharmacome/conso/efc856fb009a39e4d284269a6801f79ed3d3cf56/external/mgi-names.belns"
# DEFINE NAMESPACE MIRBASE        AS URL "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/mirbase-names.belns"
# DEFINE NAMESPACE NCBIGENE       AS URL "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/ncbigene.belns"
# DEFINE NAMESPACE PFAM           AS URL "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/pfam-names.belns"
# DEFINE NAMESPACE RGD            AS URL "https://raw.githubusercontent.com/pharmacome/conso/efc856fb009a39e4d284269a6801f79ed3d3cf56/external/rgd-names.belns"

# Namespaces hosted on https://github.com/sorgerlab/famplex
# ---------------------------------------------------------
# DEFINE NAMESPACE FPLX           AS URL "https://raw.githubusercontent.com/sorgerlab/famplex/d9ec0526c20795146a9a6aef17496efe1a36cac6/export/famplex.belns"

# Namespaces defined with regular expressions
# -------------------------------------------
# DEFINE NAMESPACE DBSNP          AS PATTERN "rs[0-9]+"
# DEFINE NAMESPACE TAXONOMY       AS PATTERN "^\d+$"
# DEFINE NAMESPACE UNIPROT        AS PATTERN "^([A-N,R-Z][0-9]([A-Z][A-Z, 0-9][A-Z, 0-9][0-9]){1,2})|([O,P,Q][0-9][A-Z, 0-9][A-Z, 0-9][A-Z, 0-9][0-9])(\.\d+)?$"
# DEFINE NAMESPACE PUBCHEM        AS PATTERN "^\d+$"

###############
# Annotations #
###############

# Annotations defined with regular expressions
# --------------------------------------------
DEFINE ANNOTATION Species       AS PATTERN "^\d+$"

# Annotations hosted on https://arty.scai.fraunhofer.de/artifactory/bel/annotation
# --------------------------------------------------------------------------------
 DEFINE ANNOTATION Anatomy       AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/anatomy/anatomy-20170511.belanno"
# DEFINE ANNOTATION CellLine      AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-line/cell-line-20170511.belanno"
# DEFINE ANNOTATION CellStructure AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-structure/cell-structure-20170511.belanno"
# DEFINE ANNOTATION Cell          AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell/cell-20170511.belanno"
# DEFINE ANNOTATION Confidence    AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/confidence/confidence-1.0.0.belanno"
# DEFINE ANNOTATION Disease       AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/disease/disease-20170511.belanno"
# DEFINE ANNOTATION Gender        AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/gender/gender-1.0.0.belanno"
# DEFINE ANNOTATION MeSHAnatomy   AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-anatomy/mesh-anatomy-20170511.belanno"
# DEFINE ANNOTATION MeSHDisease   AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-diseases/mesh-diseases-20170511.belanno"
# DEFINE ANNOTATION Subgraph      AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/neurommsig/neurommsig-1.0.3.belanno"
# DEFINE ANNOTATION TextLocation  AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/text-location/text-location-1.0.1.belanno"

##############
# Statements #
##############
SET Citation = {"PubMed", "25478017"}

#experiments done in rats using human tau peptide
SET Species = "10116"
#cell line - SHR72
SET MeSHDisease = "Alzheimer Disease"

SET Evidence = "Importantly, the analysed antibodies
showed statistically significantly higher binding activity to
the tau peptide and to mis-disordered tau 150-391/4R, than
to physiological tau 2N4R (P = 0.0003 and P = 0.0028,
respectively) (Figure 1B)."
#antibody - synthetic tau peptide
a(MESH:"Vaccines, Subunit") => complex(a(MESH:"Vaccines, Subunit"),p(HGNC:MAPT,pmod(Cys),var("p.294_305del")))
a(MESH:"Vaccines, Subunit") => complex(a(MESH:"Vaccines, Subunit"),p(CONSO:"4R tau",var("p.151_391del")))
a(MESH:"Vaccines, Subunit") -> complex(a(MESH:"Vaccines, Subunit"),p(CONSO:"Tau isoform F (441 aa)"))

SET Evidence = "Vaccination with tau vaccine
carrying DC8E8 epitope induced antibodies preferentially
recognising mis-disordered tau protein, thus discriminating
between pathological and physiological tau."
complex(a(MESH:"Vaccines, Subunit"),a(CONSO:DC8E8)) -> complex(GO:"immunoglobulin complex")
complex(GO:"immunoglobulin complex") pos complex(complex(GO:"immunoglobulin complex"),p(CONSO:"4R tau",var("p.151_391del")))


SET Evidence = "Vaccination of
rats with the tau peptide vaccine preferentially induced formation
of IgG1 antibody isotypes specific to mis-disordered
tau (151-391/4R) (Figure 1C), indicating a predominant
type 2 helper T cell (Th2) type of immune response."
p(HGNC:MAPT,pmod(Cys),var("p.294_305del")) -> a(MESH:"Immunoglobulin G")
a(MESH:"Immunoglobulin G") -> complex(a(MESH:"Immunoglobulin G"),p(CONSO:"4R tau",var("p.151_391del")))
bp(GO:"T-helper 2 cell activation") -> complex(a(MESH:"Immunoglobulin G"),p(CONSO:"4R tau",var("p.151_391del")))

SET Evidence = "Immunisation with tau vaccine induced
significant reduction of the level of highly phosphorylated
forms of truncated tau (30 to 36 kDa), tau oligomers
(above 36 kDa) and full-length tau (above 43 kDa)
revealed by measurement with pan-tau monoclonal antibody
DC25 (P = 0.0322) (Figure 2A and F)."
#detected with help of pan-tau monoclonal antibody
a(MESH:"Vaccines, Subunit") =| p(HGNC:MAPT,frag("?"),pmod(CONSO:hyperphosphorylation))
a(MESH:"Vaccines, Subunit") =| p(CONSO:"Tau oligomers")
a(MESH:"Vaccines, Subunit") =| p(HGNC:MAPT)

SET Evidence = "Moreover,
analysis with phospho-dependent monoclonal antibodies
revealed significant reduction of the levels of insoluble
tau species phosphorylated at Thr217 (pThr217, P =
0.0094; Figure 2B and F), pThr231 (DC209, P = 0.0077;
Figure 2C and F), pSer202/pThr205 (AT8, P = 0.0112;
Figure 2D and F) and pThr181 (DC179, P = 0.0100; Figure 2E
and F)."
a(MESH:"Vaccines, Subunit") =| p(HGNC:MAPT,pmod(Ph,The,217))
a(MESH:"Vaccines, Subunit") =| p(HGNC:MAPT,pmod(Ph,Thr,231))
a(MESH:"Vaccines, Subunit") =| p(HGNC:MAPT,pmod(Ph,Ser,202))
a(MESH:"Vaccines, Subunit") =| p(HGNC:MAPT,pmod(Ph,Thr,205))
a(MESH:"Vaccines, Subunit") =| p(HGNC:MAPT,pmod(Ph,Thr,181))

SET Evidence = "These results show that the immunisation
significantly reduced early forms of pathological tau
(represented by monomers, dimers and oligomers) and late
forms of pathological tau polymers (represented by paired
helical filaments (PHFs)) as well."
a(MESH:"Vaccines, Subunit") -| path(MESH:Tauopathies)
a(MESH:"Vaccines, Subunit") -| complex(p(HGNC:MAPT),p(HGNC:MAPT))
a(MESH:"Vaccines, Subunit") -| complex(p(HGNC:MAPT),p(HGNC:MAPT),p(HGNC:MAPT))
a(MESH:"Vaccines, Subunit") -| p(CONSO:"Tau oligomers")
complex(p(HGNC:MAPT),p(HGNC:MAPT)) -> path(MESH:) -> path(MESH:Tauopathies)
complex(p(HGNC:MAPT),p(HGNC:MAPT),p(HGNC:MAPT)) -> path(MESH:Tauopathies)
p(CONSO:"Tau oligomers") -> path(MESH:Tauopathies)
a(MESH:"Vaccines, Subunit") -| a(CONSO:"paired helical filaments")

 SET Evidence = ""
